Greenwich LifeSciences

GLSI

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

Greenwich LifeSciences is a small clinical-stage biotechnology company focused on developing a cancer vaccine. Its lead drug candidate, GP2, is designed to help prevent breast cancer from coming back in patients who have already been treated. The company's main customers would eventually be cancer patients and the hospitals or oncologists who treat them.

Greenwich LifeSciences makes no product revenue yet because GP2 is still being tested in clinical trials and has not been approved by the FDA. The company is based in the United States and is very small, with a market cap of roughly $200 million. Like most clinical-stage biotechs, it funds operations by raising money from investors rather than selling products. The biggest risk the company faces is that GP2 could fail in late-stage trials or not receive FDA approval, which would put the entire business in jeopardy since it currently depends on a single drug candidate.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+10.0% YoY

YoY Growth Rate

Slow EPS growth

Insider Activity

49.7%ownership

↓ Declining

Insider ownership declining — could be dilution or selling

Cash Runway

~14 months

$9M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-701.6%

Weak — -701.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial